EMRELISâ„¢ (telisotuzumab vedotin-tllv) used for previously treated adult patients with advanced non-small cell lung cancer (NSCLC) exhibiting high c-Met protein overexpression.
The creation of these implants is a direct answer to the demands of patients who need primary or revision reconstruction following a mastectomy.
The APHINITY study’s ten-year follow-up results showed that adjuvant Perjeta® (pertuzumab) added to chemotherapy and Herceptin® (trastuzumab) resulted in a clinically significant survival benefit.
The results are based on the SURMOUNT-5 Phase 3b open-label clinical trial, in which the two incretin-based drugs were directly compared over a 72-week duration.
The Phase III POTOMAC trial evaluated the effectiveness of Imfinzi in combination with BCG therapy compared to BCG therapy alone in patients with high-risk NMIBC.
In a Phase 3 trial, investigational icotrokinra led to 66% of scalp psoriasis patients and 77% of genital psoriasis patients achieving clear or almost clear skin specifically on those affected sites by Week 16.
Compared to existing CAR T treatments, the off-the-shelf experimental therapeutic CTX112TM may allow for quicker patient access.
IQVIA reported $3.829 billion in total revenue for the first quarter that ended on March 31, 2025, a 2.5% increase over the same period in 2024.
One of the most prevalent causes of chronic liver disease in the developed world, MASLD affects about 30% of the population.
Johnson & Johnson today announced significant long-term findings from the Phase 3 QUASAR study program, demonstrating that TREMFYA® (guselkumab) delivered sustained rates of clinical remission [Read More…]
